Bio-Tissue Reaches Major Milestone
MIAMI, June 1, 2011 /PRNewswire/ -- Bio-Tissue, the industry leader in Ophthalmic tissue products, announced today that it has shipped over 7,500 ProKeraŽ units since the product's inception. ProKeraŽ is the only medical device that can provide wound healing to over 350,000 annual cases of patients afflicted with damaged ocular surfaces. ProKeraŽ is a class II medical device composed of cryopreserved amniotic membrane tissue clipped into a thermoplastic ring set. "We are excited to be able to provide ProKeraŽ to the patient community that is in dire need of this innovative technology," stated Amy Tseng, President, CEO, Bio-Tissue, Inc. "We are also encouraged by the support we have received to allow this procedure to be performed and reimbursed in the physician's office setting," concluded Tseng.
ProKeraŽ combines the functionality of a symblepharon ring with the biologic actions of cryopreserved amniotic membrane to create a unique treatment option for patients presented with corneal abrasions, scarring, erosion, infectious disease and chemical/thermal burns. "ProKeraŽ is a safe and effective product that allows me to provide my patients with unparalleled clinical results without the invasiveness of surgery," said Dr. George Rosenwasser of Central Pennsylvania Eye Institute. "In addition, the ProKeraŽ device configuration enables easy insertion in the office, hospital bedside, or following other surgical procedures."
Bio-Tissue is the industry leader in ophthalmic tissue products and is engaged in the procurement, processing, storage, and distribution of cryopreserved human amniotic membrane. Bio-Tissue's patented CryoTek method ensures that the tissue retains biologic activity to promote wound healing as well as superior handling characteristics. Bio-Tissue is headquartered in Miami, FL and services customers shared with companies such as Alcon, Abbott Labs and Bausch & Lomb. For more information, please visit our website at www.biotissue.com